Harnessing the Immune System
to fight Cancer and Infectious diseases

To explore Takis opportunities, click here

Takis and Evvivax developing a 2019-nCoV Coronavirus vaccine
 

Rome, 27 January 2020 - Takis and Evvivax, two biotechnology companies present in the science park of Castel Romano, Rome announce their commitment for the development of innovative vaccines against 2019-nCoV, the new coronavirus originating in Wuhan, China. To date, the virus has caused 81 deaths and over 2,800 known infections and is rapidly expanding in various countries.

Rome, 17 March 2020 - Takis, a biotech company in Castel Romano, Rome, announces that it is ready to test its Covid-19 vaccine on pre-clinical models.
 

The authorization comes from the Ministry of Health and represents the first step in bringing the vaccine to human use. Takis researchers are the only ones in Italy and the first in Europe to access this phase of the experimentation.

Application deadline: 31.12.2019
 

Start date: 01.03.2020
(or 01.04.2020)


Requirements:
<4 years after MSc, no PhD title,
<12 months in the hosting country in the last 3 years

Our team
is recognized

for the conception and implementation of a number of innovative technologies with the goal to improve in vivo gene transfer, regulation of gene expression and immunogenicity.

 

Takis as a CRO provides a variety of research services
 

in the areas of Oncology, Immunology, Infectious Diseases and novel preclinical models.

 
 

eit HEALTH - European Union

eit Health
Takis Biotech

Harnessing the Immune System to fight cancer.

 
 
 
Takis S.r.l.

Via Castel Romano, 100
00128 Rome - Italy
P. I.V.A. 10700711004

 
 
Follow us